A detailed history of Carnegie Capital Asset Management, LLC transactions in Dexcom Inc stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 5,348 shares of DXCM stock, worth $608,014. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,348
Previous 5,410 1.15%
Holding current value
$608,014
Previous $671,000 10.43%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$114.22 - $140.1 $7,081 - $8,686
-62 Reduced 1.15%
5,348 $741,000
Q4 2023

Jan 29, 2024

BUY
$75.49 - $124.16 $75 - $124
1 Added 0.02%
5,410 $671,000
Q3 2023

Oct 10, 2023

BUY
$86.06 - $137.93 $5,163 - $8,275
60 Added 1.12%
5,409 $504,000
Q2 2023

Aug 04, 2023

BUY
$112.47 - $130.98 $3,823 - $4,453
34 Added 0.64%
5,349 $687,000
Q1 2023

Apr 19, 2023

SELL
$104.0 - $122.92 $208 - $245
-2 Reduced 0.04%
5,315 $617,000
Q4 2022

Jan 23, 2023

BUY
$84.98 - $122.67 $424 - $613
5 Added 0.09%
5,317 $0
Q2 2022

Aug 02, 2022

BUY
$67.99 - $132.89 $297,728 - $581,925
4,379 Added 469.35%
5,312 $396,000
Q2 2022

Jul 13, 2022

SELL
$67.99 - $132.89 $19,717 - $38,538
-290 Reduced 23.71%
933 $398,000
Q1 2022

Apr 11, 2022

SELL
$94.08 - $130.2 $8,373 - $11,587
-89 Reduced 6.78%
1,223 $626,000
Q4 2021

Jan 21, 2022

BUY
$129.87 - $162.82 $18,441 - $23,120
142 Added 12.14%
1,312 $704,000
Q3 2021

Oct 08, 2021

BUY
$106.71 - $143.18 $25,290 - $33,933
237 Added 25.4%
1,170 $640,000
Q1 2021

Apr 12, 2021

BUY
$84.79 - $104.74 $2,967 - $3,665
35 Added 3.9%
933 $335,000
Q4 2020

Feb 08, 2021

SELL
$78.0 - $104.5 $3,900 - $5,225
-50 Reduced 5.27%
898 $332,000
Q3 2020

Oct 13, 2020

BUY
$95.51 - $112.95 $32,282 - $38,177
338 Added 55.41%
948 $391,000
Q2 2020

Jul 09, 2020

BUY
$62.68 - $105.34 $38,234 - $64,257
610 New
610 $247,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $43.9B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Carnegie Capital Asset Management, LLC Portfolio

Follow Carnegie Capital Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.